Lead Product(s): VAR-101
Therapeutic Area: Oncology Product Name: VAR-101
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: HealthTech BioActives
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 31, 2021
Varian Bio’s lead drug candidate, VAR-101, is being developed in a topical formulation for the treatment of basal cell carcinoma. VAR-102, an oral formulation, is being developed for the treatment of a wide variety of solid tumors.